Bank of New York Mellon
TRVI icon

Bank of New York Mellon’s Trevi Therapeutics TRVI Stock Holding History

Bank of New York Mellon’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.72M Buy
306,681
+46,520
+18% +$677K ﹤0.01% 2364
2026
Q1 		$3.1M Sell
260,161
-426
-0.2% -$4.77K ﹤0.01% 2580
2025
Q4 		$3.26M Buy
260,587
+34,248
+15% +$396K ﹤0.01% 2565
2025
Q3 		$2.07M Buy
226,339
+60,074
+36% +$450K ﹤0.01% 2791
2025
Q2 		$909K Buy
166,265
+189
+0.1% +$1.18K ﹤0.01% 3177
2025
Q1 		$1.04M Buy
166,076
+25,857
+18% +$123K ﹤0.01% 3042
2024
Q4 		$578K Buy
140,219
+2,935
+2% +$9.39K ﹤0.01% 3449
2024
Q3 		$459K Sell
137,284
-41,227
-23% -$123K ﹤0.01% 3568
2024
Q2 		$532K Buy
178,511
+49,884
+39% +$139K ﹤0.01% 3555
2024
Q1 		$444K Sell
128,627
-4,754
-4% -$10.6K ﹤0.01% 3604
2023
Q4 		$179K Sell
133,381
-699
-0.5% -$1.06K ﹤0.01% 3981
2023
Q3 		$292K Buy
134,080
+2,213
+2% +$5K ﹤0.01% 3805
2023
Q2 		$315K Buy
131,867
+117,769
+835% +$297K ﹤0.01% 3804
2023
Q1 		$26.1K Hold
14,098
– – ﹤0.01% 4279
2022
Q4 		$27.2K Hold
14,098
– – ﹤0.01% 4317
2022
Q3 		$22K Buy
+14,098
New +$46.2K ﹤0.01% 4445

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon's TRVI Position: Q2 2026 in Review

Bank of New York Mellon increased its Trevi Therapeutics (TRVI) stake by 18% in Q2 2026, buying an estimated $677K and bringing the position to 306,681 shares worth $5.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2364.

Bank of New York Mellon first reported a position in TRVI in Q3 2022 and has held it in 16 quarters since. 89 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Bank of New York Mellon held 306,681 shares of Trevi Therapeutics worth $5.72M as of Q2 2026.
  • Bank of New York Mellon bought 46,520 Trevi Therapeutics shares in Q2 2026, an estimated $677K.
  • Trevi Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2364 holding.
  • Bank of New York Mellon first reported a position in Trevi Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 89 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.